LFMD News & Events

LifeMD (LFMD) announced the launch of Novo Nordisk's (NVO) new Wegovy subscription program is now available through LifeMD. "The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy," LifeMD said in a statement. LifeMD shares are up 6% to $3.81 in premarket trading.

Novo Nordisk (NVO) announced a new multi-month subscription program for Wegovy that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment. This subscription program will be available beginning March 31, 2026, through Ro, WeightWatchers (WW), LifeMD (LFMD), with Hims & Hers (HIMS), Sesame, and others to follow soon. Patients can save up to $600/year on the Wegovy pill and up to $1,200/year on the Wegovy injection with a 12-month subscription, Novo Nordisk said.